Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding Phase 2 study of BAY 2433334 after acute non-cardioembolic ischemic stroke
2019-003431-33Phase 2Completed
- Sponsor
- Bayer
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of asundexian in Noncardioembolic stroke (NCES) (4 arms), sponsored by Bayer. Started Dec 2019; status: completed.
02
Drugs
asundexian
03
Conditions
Noncardioembolic stroke (NCES)
Beyond the preview
Go deeper on 2019-003431-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003431-33.